This site is intended only for healthcare professionals residing in Malaysia
Menu
Close
Menu
Close
Data cutoff: 20 March 2020.2
Adapted from Shaw AT et al. N Engl J Med. 2020;383:2018-29.2
Data cutoff: 20 March 2020.2
Adapted from Shaw AT et al. N Engl J Med (Suppl). 2020;383:2018-29.3
This graph depicts prespecified exploratory subgroup analyses from the CROWN trial. Small patient numbers can be a limitation of subgroup analyses. These results are presented for descriptive purposes and should not be interpreted as a demonstration of efficacy in any particular subgroup.
aDefined as confirmed complete response or partial response as assessed by BICR.1,2
Data cutoff: 20 March 2020.2
Todd Bauer, MD, presents a case study of a patient with ALK+ NSCLC receiving LORVIQUA in the first-line setting.
PP-LOR-GLB-0023
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.
This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi,
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000
Fax: 603-2281 6388
Copyright © 2023 Pfizer Limited. All rights reserved.